外用薬市場：製品別、最終用途別-2025-2030年の世界予測

外用薬市場は、2023年に154億4,000万米ドルと評価され、2024年には168億6,000万米ドルに達すると予測され、CAGR 9.64％で成長し、2030年には294億3,000万米ドルに達すると予測されています。

外用薬は、皮膚や粘膜の特定部位に直接塗布する製剤で、局所的な治療を目的としています。これらの薬剤は、様々な皮膚症状、疼痛緩和、感染症、炎症の管理に不可欠であり、副作用を軽減した全身薬に代わる選択肢を提供します。応用範囲は皮膚科、眼科、歯科、その他に及び、治療と美容の両方の目的で使用されます。高齢化社会の拡大や皮膚疾患の有病率の上昇に伴い、非侵襲的な治療を好む患者が増加していることから、最終用途市場には病院、診療所、在宅医療の現場が含まれます。市場に影響を与える主な成長要因としては、ナノテクノロジーや生物製剤の使用など製剤化技術の進歩、消費者意識の高まりによるセルフメディケーション志向の高まりなどが挙げられます。アジア太平洋やラテンアメリカなど、ヘルスケア支出が増加し、アンメット・メディカル・ニーズが高まっている地域市場には、潜在的なビジネスチャンスが眠っています。企業は個別化医療に軸足を移し、3Dプリンティングのようなイノベーションを活用してカスタマイズを行い、個々の患者のニーズにより効果的に対応することが推奨されます。しかし、同市場は、製品承認プロセスにおける規制上の課題や、全身に吸収されることなく望ましい有効性と安定性を達成するための製剤上の難しさといった限界に直面しています。激しい研究開発コストを特徴とする競合情勢は、特に新規参入者にとっての課題となっています。市場関係者にとっては、ドラッグデリバリー技術の強化、多機能製剤の開発、バイオベース製品の可能性への投資といった革新的分野が、有利な見通しをもたらしています。市場情勢に関する洞察によれば、市場は適度に断片化されており、主要プレーヤーは戦略的合併や買収を通じて、常にポートフォリオを拡大しようとしています。消費者の動向、規制要件を理解し、先進的な送達メカニズムの研究開発に投資することは、この進化する市場で持続的な成長を遂げ、競争優位に立つために極めて重要です。

市場力学：急速に進化する外用薬市場の主要市場インサイトを公開

外用薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 皮膚疾患および糖尿病の罹患率の上昇
  • 自己投与薬やステロイドを含まない外用薬の需要の増加
  • 外用薬に対する政府の好意的な承認
• 市場抑制要因
  • 外用治療に伴う刺激やアレルギー
• 市場機会
  • 外用薬処方の革新
  • ドラッグデリバリーシステムの進歩
• 市場の課題
  • 外用薬の複雑な処方

ポーターの5つの力：外用薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：外用薬市場における外部からの影響の把握

外部マクロ環境要因は、外用薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析外用薬市場における競合情勢の把握

外用薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス外用薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、外用薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨外用薬市場における成功への道筋を描く

外用薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 皮膚疾患および糖尿病の発生率の上昇
    • 自己投与薬とステロイドを含まない外用薬の需要増加
    • 外用薬に対する政府の好意的な承認
  • 抑制要因
    • 局所治療に伴う刺激とアレルギー
  • 機会
    • 外用薬製剤の革新
    • ドラッグデリバリーシステムの進歩
  • 課題
    • 外用薬の複雑な定式化
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 外用薬市場：製品別

• 液体製剤
  • ソリューション
  • サスペンション
• 半固形製剤
  • クリーム
  • ゲル
  • ローション
  • 軟膏
  • ペースト
• 固形製剤
  • 粉末
  • 坐薬
• 経皮吸収製品
  • 経皮パッチ
  • 経皮吸収型半固形剤

第7章 外用薬市場：最終用途別

• 火傷センター
• ホームケア設定
• 病院・クリニック

第8章 南北アメリカの外用薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の外用薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの外用薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Almirall, S.A
• Bausch Health Companies Inc.
• Bayer AG
• Cigna Health and Life Insurance Company
• Concert Pharmaceuticals
• Eli Lilly and Company
• GlaxoSmithkline PLC
• Hisamitsu Pharmaceuticals Co. Inc.
• Johnson & Johnson Services, Inc.
• LEO Pharma A/S
• Lupin Limited
• Mayne Pharma Group Limited
• Mylan N.V.
• Tergus Pharma

LIST OF FIGURES

• FIGURE 1. TOPICAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. TOPICAL DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TOPICAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TOPICAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TOPICAL DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TOPICAL DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. TOPICAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. TOPICAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TOPICAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TOPICAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TOPICAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TOPICAL DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TOPICAL DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TOPICAL DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TOPICAL DRUGS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TOPICAL DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TOPICAL DRUGS MARKET SIZE, BY PASTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TOPICAL DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL SEMI-SOLIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL TOPICAL DRUGS MARKET SIZE, BY BURN CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL TOPICAL DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL TOPICAL DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. CANADA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 53. CANADA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 54. CANADA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 55. CANADA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES TOPICAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. CHINA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. CHINA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 84. CHINA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 85. CHINA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 86. CHINA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 87. CHINA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. INDIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. INDIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 90. INDIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 91. INDIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 92. INDIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 93. INDIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA TOPICAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 191. ITALY TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. ITALY TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 193. ITALY TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 194. ITALY TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 195. ITALY TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 196. ITALY TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 215. POLAND TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. POLAND TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 217. POLAND TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 218. POLAND TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 219. POLAND TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 220. POLAND TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 221. QATAR TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. QATAR TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 223. QATAR TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 224. QATAR TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 225. QATAR TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 226. QATAR TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY TRANSDERMAL PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM TOPICAL DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 281. TOPICAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 282. TOPICAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Topical Drugs Market was valued at USD 15.44 billion in 2023, expected to reach USD 16.86 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 29.43 billion by 2030.

Topical drugs are formulations applied directly to a specific area of the skin or mucous membranes, aimed at providing localized treatment. These drugs are essential in managing various skin conditions, pain relief, infections, and inflammation, offering an alternative to systemic medications with reduced side effects. The application scope encompasses dermatological, ophthalmic, dental, alongside others, serving both therapeutic and cosmetic purposes. With an expanding aging population and increasing prevalence of skin diseases, the end-use market includes hospitals, clinics, and home-care settings, driven by a patient preference for non-invasive treatments. Key growth factors influencing the market include technological advancements in formulation techniques like the use of nanotechnology and biologics, and an increasing inclination towards self-medication practices boosted by heightened consumer awareness. Potential opportunities lie in geographic markets with rising healthcare expenditures and unmet medical needs, such as in Asia-Pacific and Latin America. Companies are advised to pivot towards personalized medicine and leverage innovations like 3D printing for customization, addressing individual patient needs more effectively. However, the market faces limitations, such as the regulatory challenges of product approval processes, and formulation difficulties in achieving the desired efficacy and stability without systemic absorption. The competitive landscape, characterized by intense R&D costs, particularly poses a challenge for new entrants. For market players, innovation areas such as enhancing drug delivery technologies, developing multi-functional formulations, and investing in the potential of bio-based products present lucrative prospects. Insights into the nature of the market suggest a moderately fragmented landscape, with key players constantly attempting to broaden their portfolios through strategic mergers and acquisitions. Understanding consumer trends, regulatory requirements, and investing in R&D for advanced delivery mechanisms will be crucial for sustained growth and a competitive edge in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Topical Drugs Market

The Topical Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of skin disorders, and diabetes
  • Increasing demand for self-administered drugs and steroid-free topical medication
  • Favorable government approvals for topical drugs
• Market Restraints
  • Irritations and allergies associated with topical treatments
• Market Opportunities
  • Innovation in topical drug formulations
  • Advancements in drug delivery systems
• Market Challenges
  • Complex formulations of topical drugs

Porter's Five Forces: A Strategic Tool for Navigating the Topical Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Topical Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Topical Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Topical Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Topical Drugs Market

A detailed market share analysis in the Topical Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Topical Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Topical Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Topical Drugs Market

A strategic analysis of the Topical Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Topical Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, S.A, Bausch Health Companies Inc., Bayer AG, Cigna Health and Life Insurance Company, Concert Pharmaceuticals, Eli Lilly and Company, GlaxoSmithkline PLC, Hisamitsu Pharmaceuticals Co. Inc., Johnson & Johnson Services, Inc., LEO Pharma A/S, Lupin Limited, Mayne Pharma Group Limited, Mylan N.V., and Tergus Pharma.

Market Segmentation & Coverage

This research report categorizes the Topical Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Liquid Formulations, Semi-Solid Formulations, Solid Formulations, and Transdermal Products. The Liquid Formulations is further studied across Solutions and Suspensions. The Semi-Solid Formulations is further studied across Creams, Gel, Lotions, Ointments, and Pastes. The Solid Formulations is further studied across Powders and Suppositories. The Transdermal Products is further studied across Transdermal Patches and Transdermal Semi-Solids.
• Based on End-use, market is studied across Burn Centers, Home Care Settings, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of skin disorders, and diabetes
    • 5.1.1.2. Increasing demand for self-administered drugs and steroid-free topical medication
    • 5.1.1.3. Favorable government approvals for topical drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Irritations and allergies associated with topical treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovation in topical drug formulations
    • 5.1.3.2. Advancements in drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Complex formulations of topical drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Topical Drugs Market, by Product

• 6.1. Introduction
• 6.2. Liquid Formulations
  • 6.2.1. Solutions
  • 6.2.2. Suspensions
• 6.3. Semi-Solid Formulations
  • 6.3.1. Creams
  • 6.3.2. Gel
  • 6.3.3. Lotions
  • 6.3.4. Ointments
  • 6.3.5. Pastes
• 6.4. Solid Formulations
  • 6.4.1. Powders
  • 6.4.2. Suppositories
• 6.5. Transdermal Products
  • 6.5.1. Transdermal Patches
  • 6.5.2. Transdermal Semi-Solids

7. Topical Drugs Market, by End-use

• 7.1. Introduction
• 7.2. Burn Centers
• 7.3. Home Care Settings
• 7.4. Hospitals & Clinics

8. Americas Topical Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Topical Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Topical Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Almirall, S.A
• 3. Bausch Health Companies Inc.
• 4. Bayer AG
• 5. Cigna Health and Life Insurance Company
• 6. Concert Pharmaceuticals
• 7. Eli Lilly and Company
• 8. GlaxoSmithkline PLC
• 9. Hisamitsu Pharmaceuticals Co. Inc.
• 10. Johnson & Johnson Services, Inc.
• 11. LEO Pharma A/S
• 12. Lupin Limited
• 13. Mayne Pharma Group Limited
• 14. Mylan N.V.
• 15. Tergus Pharma